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Dallas, Texas; and Richmond, Virginia
Patients with a suspected acute coronary syndrome and left bundle branch block (LBBB) present a unique diag-
nostic and therapeutic challenge to the clinician. Although current guidelines recommend that patients with new
or presumed new LBBB undergo early reperfusion therapy, data suggest that only a minority of patients with
LBBB are ultimately diagnosed with acute myocardial infarction, regardless of LBBB chronicity, and that a signifi-
cant proportion of patients will not have an occluded culprit artery at cardiac catheterization. The current treat-
ment approach exposes a significant proportion of patients to the risks of fibrinolytic therapy without the likeli-
hood of significant benefit and leads to increased rates of false-positive cardiac catheterization laboratory
activation, unnecessary risks, and costs. Therefore, alternative strategies to those for patients with ST-segment
elevation myocardial infarction are needed to guide selection of appropriate patients with a suspected acute
coronary syndrome and LBBB for urgent reperfusion therapy. In this article, we describe the evolving epidemiol-
ogy of LBBB in acute coronary syndromes and discuss controversies related to current clinical practice. We pro-
pose a more judicious diagnostic approach among clinically stable patients with LBBB who do not have electro-
cardiographic findings highly specific for ST-segment elevation myocardial infarction. (J Am Coll Cardiol 2012;
60:96–105) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.054Patients with a suspected acute coronary syndrome (ACS)
in the setting of left bundle branch block (LBBB) present an
important diagnostic and therapeutic challenge to the cli-
nician. Not only is the electrocardiographic (ECG) diagno-
sis of acute myocardial infarction (AMI) difficult because of
so-called masking of characteristic ECG changes by altered
ventricular depolarization, but also these patients may be at
higher risk for AMI, congestive heart failure, and death
compared with patients without bundle branch block (BBB)
(1–3). Although current guidelines from the American
College of Cardiology/American Heart Association (4) and
the European Society of Cardiology (5) recommend that
patients with new or presumed new LBBB undergo early
reperfusion therapy with fibrinolysis or percutaneous coro-
nary intervention (PCI), these recommendations are based
on studies performed more than 20 years ago, and the
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patient subsets.
In this paper, we review the pathophysiologic mecha-
nisms underlying LBBB in AMI and the historical context,
epidemiology, and outcomes of the current recommended
treatment approach; discuss controversies in clinical prac-
tice; and suggest future strategies for improvement in the
efficiency and outcomes of care for patients with LBBB.
Pathophysiology of LBBB in AMI
The intraventricular conduction system of the left ventricle
is composed of fibers of the bundle of His that become the
main left bundle branch and then divide into anterior and
posterior fascicles, further branching to become the distal
conduction system. In contrast to the right bundle branch,
which is a discrete structure that can be injured acutely with
a small focal insult, the left bundle branch is a large and
diffuse structure that typically requires a large insult to lead
to acute injury (6). When a new LBBB is caused by AMI,
the site of infarction usually is anterior or anteroseptal (7),
with the infarction involving a large myocardial territory.
Inferior or posterior infarctions uncommonly may result in
a new LBBB from involvement of the more proximal
portion of the conduction system supplied by the atrioven-
tricular nodal artery. However, most cases of LBBB in AMI
are not a result of focal infarctions, because either a discrete
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dial damage involving a large portion of the distal conduc-
tion system including both fascicles would be required to
cause LBBB (Fig. 1).
Although LBBB can occur de novo in AMI, it is more
often a pre-existing marker of underlying structural heart
disease, and thus reflective of the patient’s baseline cardio-
vascular risk. In these cases, LBBB may be the result of an
aging or fibrotic conduction system, or both; chronic isch-
emic heart disease; left ventricular hypertrophy (most com-
monly from long-standing hypertension); adverse ventricu-
lar remodeling resulting from congestive heart failure; or
valvular heart disease. It is not possible to determine the
chronicity of LBBB without reviewing previous ECG
tracings, because the onset of LBBB usually is asymptom-
atic. LBBB in AMI may be transient or permanent,
although early accounts note that most cases of permanent
LBBB were not the result of an acute transmural infarction,
because true AMI-associated LBBB was associated with
very high mortality (8).
Historical Perspective
Recognition of LBBB in AMI dates back to 1917 in an
account by Oppenheimer and Rothschild (9). Early descrip-
tions of BBB in AMI reported an incidence of 10% to 15%
and a mortality rate of 42% to 63% (10). Patients with BBB
tended to be significantly older and to have an increased
frequency of hypertension, congestive heart failure, previous
myocardial infarction, and cardiogenic shock. It is, there-
fore, difficult to discern if historical studies documenting the
significantly increased mortality risk (approximately 2-fold)
in BBB were confounded by age and comorbid conditions.
Additionally, studies included patients with both LBBB and
right BBB, recorded ECG data at widely varied time points,
lacked discrimination between new and old infarction, and
had limited diagnostic resources to confirm AMI at presen-
tation (11).
For more than 60 years, clinicians have recognized that a
diagnosis of AMI in the setting of LBBB is especially
challenging (12). Because left ventricular activation occurs
much later in LBBB and the initial septal activation
advances from right to left (opposite of the normal situa-
tion), septal Q waves indicative of an AMI are absent.
Additionally, secondary ST-T wave abnormalities that oc-
cur in LBBB obscure the recognition of injury currents in
ischemia and infarction. Despite the suggestion of multiple
criteria for diagnosis of AMI in the setting of LBBB, it
generally was believed that clinicians remained largely blind
to ECG changes in patients with LBBB (12). In 1996,
Sgarbossa et al. (13) published an analysis from the
GUSTO-1 (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries-1)
trial evaluating multiple different ECG criteria that had
been suggested as being potentially useful for the diagnosis
of AMI in the setting of LBBB. Of these, ST-segmentelevation concordant with the
major QRS deflection in any lead
and ST-segment depression in
leads V1, V2, or V3 had odds
atios for AMI of 25.2 (95%
onfidence interval [CI]: 11.6 to
4.7) and 6.0 (95% CI: 1.9 to
9.3), respectively; discordant ST-
egment elevation of 5 mm or
ore in any lead had a weaker
ssociation (odds ratio: 4.3, 95%
I: 1.8 to 10.6). When com-
ined, these 3 ECG criteria
ielded a sensitivity and specific-
ty of approximately 78% and
0%, respectively. Subsequent
alidation studies have confirmed
hat ST-segment concordance
riteria are highly specific for
MI, but generally have re-
orted much lower sensitivities than the initial study
14,15). Currently, the Sgarbossa criteria are used most exten-
ively to diagnose AMI in the setting of a known chronic
BBB. Although data exist to support use of the Sgarbossa
riteria in new or indeterminate-age LBBB, current guidelines
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AMI  acute myocardial
infarction
BBB  bundle branch block
CI  confidence interval
ECG  electrocardiography
LBBB  left bundle branch
block
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
Figure 1 Anatomy of the Left Bundle Branch
The left bundle branch comprises the main left bundle and distal anterior and
posterior fascicles. Left bundle branch block (LBBB) resulting from an incident
myocardial infarction requires a lesion just distal to the bundle of His (1) or
extensive myocardial damage involving a large portion of the distal conduction
system, including both fascicles (2 and 3).
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their recommendations.
Epidemiology and Clinical Trial Results
Individuals with LBBB represent approximately 2% of all
patients who seek treatment with suspected ACS (Table 1).
They are more likely to be older, to be female, and to have
a history of pre-existing cardiovascular disease, hyperten-
sion, and congestive heart failure than non-BBB patients
with ACS (1,16). Patients with LBBB also have a greater
likelihood of major adverse cardiac events, including death,
AMI, stroke, and revascularization over long-term
follow-up compared with patients without BBB (1). How-
ever, these observations may be explained, in large part, by
underlying ischemic and structural heart disease that is the
substrate for the development of LBBB, rather than by the
LBBB itself. Because LBBB is strongly related to advancing
age, which, in turn, is associated with many chronic disease
states and the development of cardiac conduction disease,
LBBB may be an integrative marker of overall cardiac risk,
rather than an independent contributor to morbidity and
mortality (16).
The excess mortality risk associated with LBBB in AMI
compared with normal conduction is unclear. Early obser-
vations of high mortality rates may have been confounded
Prevalence of LBBB and AMI in Studies of Patients With SuspecteTable 1 Prevalence of LBBB and AMI in Studies of Patients Wi
First Author (Ref. #) Yea
Randomized trials or registries enrolling patients with high suspicion or
documentation of AMI, STEMI, or new LBBB
Sgarbossa et al. (13) 199
Cannon et al. (3) 199
Wong et al. (22) 200
Al-Faleh et al. (23) 200
Lopes et al. (36) 201
Jain et al. (42) 201
Subtotal (n  6)
More broadly representative studies of patients with suspected AMI
presenting to ED
Rude et al. (52) 198
Fesmire et al. (53) 198
Otto and Aufderheide (54) 199
Kudenchuk et al. (55) 199
Edhouse et al. (56) 199
Shlipak et al. (39) 199
Li et al. (15) 200
Kontos et al. (14) 200
Gunnarsson et al. (43) 200
Maynard et al. (57) 200
Chang et al. (31) 200
Bansilal et al. (1) 201
Kontos et al. (34) 201
Subtotal (n  13)
Total (n  19)
*Does not include studies of patients with LBBB only. †Includes patients in all studies (n  1,690
ACS  acute coronary syndrome; AMI  acute myocardial infarction; ED  emergency department; LB
infarction.by comorbid conditions or delays in diagnosis and treatment
because ECG criteria to diagnose AMI in LBBB were not
available. More contemporary studies from the reperfusion
era reported that patients with BBB were less likely to
receive immediate reperfusion therapy (including fibrinoly-
sis or PCI), had longer delays between hospital arrival and
initiation of reperfusion therapies, were less likely to receive
evidence-based medical therapy, and had a 34% to 64%
increased risk of in-hospital death, even after adjustment for
potential confounders (2). However, right BBB was ob-
served to have a greater risk for mortality than LBBB, and
other investigators have not been able to confirm an
independent mortality risk of LBBB (16–18).
Initial clinical trials investigating the efficacy of fibrino-
lytic therapy included a broad range of patients, including
those with ST-segment elevation, ST-segment depression,
and BBB. For example, the ISIS-2 (Second International
Study of Infarct Survival) trial (19) randomized 17,187
subjects within 24 h after the onset of suspected AMI to
streptokinase alone, aspirin alone, streptokinase plus aspirin,
or placebo in addition to usual care. BBB (left or right) was
present in 1,032 (6%) of subjects at randomization; those
with BBB had numerically lower rates of death with each
intervention versus placebo (83 vs. 102, 74 vs. 111, and 29
vs. 57 in the streptokinase, aspirin, and streptokinase plus
spected ACS
Total No. of
Patients
No. of Patients
With LBBB (%)
No. of LBBB Patients
With AMI (%)
26,003 145 (0.6) 131 (90)
1,416 127 (9) 40 (31)
17,073 300 (1.8) 242 (81)
22,839 267 (1.2) 158 (63)
5,742 98 (1.7) 85 (87)
892 36 (4) 12 (33)
73,965 973 (1.3) 668 (67)
3,697 178 (4.8) 82 (46)
440 24 (5.5) 3 (13)
428 18 (4.2) 5 (28)
3,027 57 (1.9) 20 (35)
797 50 (6) 26 (52)
n/a 83 (100) 26 (31)
n/a 190 (100) 25 (13)
7,725 182 (2.4) 24 (13)
n/a 158 (100) 76 (48)
n/a 56 (100) 18 (32)
7,937 191 (2.4) 11 (6)
2,271 102 (4.5) 5 (5)
n/a 401 (100) 116 (29)
26,322 802 (3.0)* 437 (26)†
100,287 1,775 (1.8)* 1,105 (42)‡
ludes patients in all studies (n  2,663).d ACSth Su
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per lo Studio della Streptochinasi nell’Infarto Miocardico)
trial (20) randomized 11,802 subjects with suspected AMI
to streptokinase or usual care, with BBB observed in 661
(5.6%) subjects. The 21-day mortality was no different
between subjects with BBB receiving streptokinase (8%)
versus those receiving placebo (8.6%), with a relative risk of
0.92 (95% CI: 0.53 to 1.60).
An analysis of pooled data from 9 fibrinolytic trials
including more than 58,000 patients with suspected AMI,
including both patients with ST-segment elevation myocar-
dial infarction (STEMI) and those with BBB, provided
more statistical power for evaluation of subgroups with BBB
(Table 2). Subjects with BBB (n 2,146) treated with early
brinolysis had lower mortality (18.7% vs. 23.6%) than
hose treated with placebo, although the overall benefit was
artially offset by an increase in stroke (2.1% vs. 1.1%) and
ajor bleeding (1.3% vs. 0.3%) (21). These data form the
asis for the current recommendations to treat new or
resumed new LBBB as a STEMI equivalent requiring
rgent reperfusion therapy. However, an important limita-
ion not frequently recognized is that the primary analysis
n which these recommendations are based did not differ-
ntiate between the type or chronicity of BBB and subjects
ith BBB represented only 3.6% of the total cohort.
Data from more recent fibrinolytic trials, with specific
nclusion criteria for patients with presumed new LBBB,
rovide more direct comparisons of outcomes between
TEMI and LBBB. For example, the HERO-2 (Hirulog
nd Early Reperfusion or Occlusion) trial demonstrated that
atients with new or presumed new LBBB had a lower
ncidence of enzymatically confirmed AMI (80.7% vs.
8.7%, p  0.006) and lower 30-day mortality (16% vs.
2.7%, p  0.027) than matched STEMI controls. Differ-
nces were observed, however, between LBBB patients with
nd without Sgarbossa ST-segment concordance criteria:
hose without concordance had a lower adjusted risk of
0-day mortality compared with those with STEMI (odds
atio: 0.52, 95% CI: 0.33 to 0.80), whereas those meeting
oncordance criteria had a similar risk (odds ratio: 1.37, 95%
I: 0.78 to 2.47) (22). Similarly, in the ASSENT (Assess-
ent of the Safety and Efficacy of a New Thrombolytic) -2
nd -3 trials, 37.5% of LBBB versus 15.6% of STEMI
atients (p  0.001) did not have AMI enzymatically
onfirmed, and mortality was found to differ between
atients with and without Sgarbossa concordance. In this
Clinical Outcomes in Patients With BBB in Randomized ControlledIntraveno s Fibrinolytic Therapy Versus Standard Car in AMI*Table 2 Clin ca Outcomes in Patients With BBB in Ra domizeIntravenous Fibrinolytic Therapy Versus Standard Care
Patient Population
Death
Fibrinolytic Control
All patients (n  58,600) 2,820 (9.6) 3,357 (11.5)
Patients with BBB (n  2,146)† 188 (18.7) 242 (23.6)Values are n (%). *Data from the FTT Collaborative Group (21). †Includes patients with both LBBB and R
BBB  bundle branch block; RBBB  right bundle branch block. Other abbreviations as in Table 1.nalysis, the adjusted relative risk of mortality at 1 year
mong patients with LBBB and Sgarbossa concordance
score 3) compared with STEMI was 3.8 (95% CI: 2.17
o 6.78); however, those with LBBB but without ST-
egment concordance had a similar risk of 1-year mortality
ompared with STEMI patients (relative risk: 0.91, 95%
I: 0.47 to 1.77) (23). It should be noted that enrollment in
hese trials required a high clinical suspicion for AMI, and
evertheless, a substantially higher proportion of LBBB
atients did not have AMI confirmed, especially among
hose without concordant ECG changes. Taken together,
hese data suggest that (1) patients with LBBB have
eterogeneous outcomes with fibrinolytic therapy in part
ecause of the significant variability in AMI incidence
mong this group and (2) Sgarbossa concordance on ECG
ay identify a high-risk population with similar (or worse)
utcomes compared with STEMI.
More contemporary trials comparing the use of primary
CI with fibrinolysis have not provided much additional
nformation regarding the benefit of urgent reperfusion
trategies in patients with LBBB. Although the clinical
uperiority of primary PCI over fibrinolysis has been estab-
ished, there are limited randomized trial data comparing
he 2 therapies in patients with LBBB. Only 7 of the 23
rials reported in the meta-analysis by Keeley et al. (24)
ncluded patients with LBBB; efficacy or safety outcomes in
atient subgroups with LBBB have not been reported from
hese trials, and the largest trial to date specifically excluded
uch patients (25). Thus, randomized clinical trial data
stablishing a clear benefit of urgent reperfusion therapy in
atients with LBBB in the modern era are lacking.
linical Controversies
he initial rationale for using ST-segment elevation on
CG as a decision point for early reperfusion therapy in
atients with suspected ACS was the high specificity for
dentifying patients who had complete occlusion of a coro-
ary artery and who were most likely to benefit from
reatment with a fibrinolytic agent. In this regard, a new (or
resumably new) LBBB was thought to be equivalent to
T-segment elevation. However, recent data have called
nto question the principle that suspected ACS with a new
r presumed new LBBB should be treated as a STEMI
quivalent. In the fibrinolytic era, a diagnosis of AMI typically
as not confirmed angiographically, but rather biochemically
oftrolled Trials of
I*
Stroke Bleeding
Fibrinolytic Control Fibrinolytic Control
340 (1.2) 224 (0.8) 325 (1.1) 111 (0.4)
21 (2.1) 11 (1.1) 13 (1.3) 3 (0.3)Trialsd Con
in AMBBB.
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As primary PCI became more feasible, a larger number of
studies were able to confirm AMI angiographically. Overall,
these studies have demonstrated that less than half of all
patients with suspected ACS and LBBB ultimately will be
diagnosed with an AMI (Table 1). Moreover, a significant
proportion of those patients with AMI will not have an
occluded culprit artery at catheterization, and thus are
classified more appropriately as having a non–ST-segment
elevation myocardial infarction (NSTEMI), unstable an-
gina, or non-ACS presentation (Table 3). This has impor-
tant implications for the treatment of patients with pre-
sumed new LBBB who do not have immediate access to
coronary angiography. If many of the patients with LBBB
do not have AMI, they are unlikely to benefit from early
reperfusion therapy. In addition, fibrinolytics have been
shown to offer no benefit, and in fact may be harmful, to
patients with NSTEMI (26).
The significant variability in the prevalence of AMI
complicated by LBBB reported in prior studies may be
partially explained by diagnostic criteria with poor specific-
ity for AMI. Because circulating biochemical markers of
myocardial necrosis can be associated with structural heart
disease, heart failure, kidney disease, and other comorbid
conditions (27,28), patients with LBBB may have been
misclassified previously as having AMI based solely on
biochemical testing. Moreover, because elevated cardiac
biomarkers are associated with greater risk in many non-
ACS conditions compared with ACS (29), it is likely that
some of the excess risk associated with LBBB reflects
comorbid conditions not related to incident LBBB.
In addition to the more accurate classification of AMI in
the primary PCI era, it is also possible that the distribution
of new versus old LBBB has changed. For example, in 2
reports from the 1970s, the proportion of AMI patients
with new (compared with old) LBBB ranged from 53% to
61% (7,30). In contrast, a recent study by Chang et al. (31)
reported that new LBBB was observed in only 29% of
LBBB patients. Because patients hospitalized with myocar-
dial infarction increasingly are older; are more likely to be
Prevalence of STEMI-Equivalent AMIin Angiographic Studies ofatients With uspect d ACS and LBBB
Table 3
Prevalenc of STEMI-Equivalent AMI
in Angiographic Studies of
Patients With Suspected ACS and LBBB
First Author
(Ref. #) Year
No. of Patients With Occluded
Culprit Artery/Total With LBBB (%)
New or Presumed
New LBBB Old LBBB
Larson et al. (35) 2007 20/36 (56) n/a
Chang et al. (31) 2009 4/55 (7) 7/136 (5)
Lopes et al. (36) 2011 60/98 (61) n/a
Jain et al. (42) 2011 5/36 (14) n/a
Total (n  4) 89/225 (40) 7/136 (5)b
Values are n/N (%).
Abbreviations as in Table 1.female; are more likely to have coexisting conditions such as
hypertension, dyslipidemia, and diabetes mellitus; and are
more likely to have undergone previous coronary revascu-
larization (32), the prevalence of chronic LBBB likely is
increasing, despite a general decline in overall incident
STEMI. This phenomenon suggests that chronic LBBB
may have become more common, whereas incident LBBB
in AMI has decreased, because of longer life expectancy and
better survival for patients with heart failure and other
coexisting conditions (33). Furthermore, other studies have
demonstrated no difference in the prevalence of AMI
between patients with chronic LBBB and new or presumed
new LBBB (31,34), suggesting that true myocardial
infarction-associated LBBB is indeed rare.
As pressures to reduce reperfusion times have increased,
and acute cardiac care—both in the emergency department
and in the ambulance—is increasingly driven by protocol,
LBBB of unknown duration has emerged as a frequent
reason for false activation of the cardiac catheterization
laboratory for primary PCI. In this setting, a false activation
is defined as an activation in which the coronary angiogram
does not identify a culprit artery consistent with STEMI.
Because only a minority of patients with LBBB ultimately
are diagnosed with AMI, false-positive cardiac catheteriza-
tion laboratory activation is frequent. In a single-center
study of 1,335 patients, Larson et al. (35) reported that the
prevalence, of false-positive catheterization laboratory acti-
vation was 14% overall, but among patients with LBBB at
presentation, the rate of false activation was 44%. These
findings have been confirmed in a recent PCI study dem-
onstrating that 39% of the 98 patients with new LBBB,
most of whom even had concordant ST-segment changes
on ECG, did not have an occluded culprit coronary artery
on angiography (36). In our experience, it is not uncommon
for catheterization laboratory activation to occur in patients
with atypical chest pain or evidence of new onset heart
failure in whom LBBB is present but cannot be confirmed
to be old.
Urgent catheterization for all-comers can lead to an
increased risk of complications related to the invasive
procedure, resulting in prolonged hospital length of stay and
higher costs and decreased quality of life for providers (37).
n centers where primary PCI is not readily available, these
ssues obviously are more concerning given the risks of
leeding, particularly intracranial hemorrhage, with fibrino-
ytic therapy; the risks of fibrinolytic therapy may be
agnified in patients with LBBB who generally are older
nd have higher rates of hypertension. Alternatively, given
hat patients with LBBB are less likely to receive reperfusion
herapy (because of comorbid conditions or lack of diagnos-
ic accuracy of the ECG procedure), there is appropriate
oncern that delays in diagnosis and therapy may lead to
issed opportunities to reduce morbidity and mortality in
atients with LBBB and true AMI (38). For example, a
ecision analysis found that routine administration of fi-
rinolytic therapy to all patients with LBBB and possible
m
S
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reduction; however, this approach may lead to unnecessary
administration of fibrinolytic therapy to most patients who
do not have AMI (39). It should be noted that this analysis
was performed more than 10 years ago, based on epidemi-
ological data suggesting a higher proportion of STEMI-
equivalent AMI in patients with LBBB than seems to be
the case today. In the modern era, the risk-to-benefit ratio
may be even less favorable. Therefore, as systems of care
improve and delays in transfer for primary PCI decrease,
applying a routine transfer strategy for patients with sus-
pected AMI and LBBB may preserve the benefit of reper-
fusion therapy for the highest-risk patients while minimizing
potential harm associated with administering fibrinolytic ther-
apy to patients without occluded arteries.
Sgarbossa Electrocardiogram Criteria for the Diagnosis of EvolvingTable 4 Sgarbossa Electrocardiogram Criteria for the Diagnosis
ECG Criteria†
Assigned Point
Value
ST-segment elevation 1 mm and
concordant with QRS complex
5
ST-segment depression 1 mm in
lead V1, V2, or V3
3
ST-segment elevation 5 mm and
discordant with QRS complex
2
*Data from Tabas et al. (41). Sensitivity, specificity, and positive and negative likelihood ratios a
deviation is measured at the J point. Concordance and discordance of ST segments are determin
ECG  electrocardiography; other abbreviations as in Table 1.
Figure 2 Electrocardiograms Demonstrating the 3 Sgarbossa C
the Diagnosis of Acute Myocardial Infarction in a Pat
(A) Electrocardiography (ECG) image showing ST-segment elevation of at least 1 m
ST-segment elevation of at least 5 mm that is discordant with the QRS complex (a
in leads V and V (arrows). ECG images reprinted with permission courtesy of EC2 3Do the Sgarbossa Criteria Help?
The Sgarbossa criteria (13), as proposed in 1996, are listed
in Table 4 and include ST-segment elevation of 1 mm or
ore concordant with the QRS complex in any lead;
T-segment depression of 1 mm or more in lead V1, V2, or
V3; and ST-segment elevation of 5 mm or more discordant
with the QRS complex in any lead (Fig. 2). These criteria
are weighted differently to reflect their varied estimated
probability for AMI diagnosis. The original study by Sgar-
bossa et al. (13) reported that the ST-segment concordance
criteria (score 3) were the most accurate for AMI diag-
nosis. The authors found that ST-segment discordance
(score of 2) was of limited value because of poor specificity
and suggested that patients with ST-segment discordance
in the Presence of LBBB*volving AMI in the Presence of LBBB*
nsitivity (%) Specificity (%)
Positive
Likelihood Ratio
Negative
Likelihood Ratio
0 (18–23) 98 (97–99) 7.9 (4.5–13.8) 0.81 (0.78–0.85)
1 (37–45) 85 (82–88) 2.0 (1.1–3.8) 0.81 (0.67–0.99)
nted as summary statistics (95% confidence intervals) for scores of  3 and  2. †ST-segment
omparison with the main direction of the QRS complex.
a for
ith LBBB
t is concordant with the QRS complex (arrows, leads V5 and V6) and
lead V3). (B) ECG image showing ST-segment depression of at least 1 mm
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testing. Several prospective studies and a recent meta-
analysis generally have concluded that the Sgarbossa criteria,
with the exception of discordant ST-segment elevation, are
highly specific for the diagnosis of AMI in the setting of
LBBB, have good interobserver agreement (  0.81), and
have similar usefulness whether the LBBB is new or old
(40). Recent validation studies have confirmed that a Sgar-
bossa score of 3 or more (requiring either concordant
ST-segment elevation of 1 mm or more or ST-segment
depression of 1 mm or more in lead V1, V2, or V3) has
pecificity for AMI of more than 95% and is associated with
igher 30-day mortality compared with LBBB patients with
iscordant ST-segment elevation alone (22,23,41). For
xample, Kontos et al. (34) studied 401 patients in the
mergency department with suspected AMI and found that
T-segment concordant elevation or depression was an
ndependent predictor of AMI (odds ratio: 17.0, 95% CI:
.4 to 81, p  0.001) and 30-day mortality (odds ratio: 4.3,
5% CI: 1.3 to 15, p  0.02). Other studies have concluded
hat ST-segment elevation concordance is the single most
pecific criterion for the diagnosis of AMI and improves
dentification of individuals who will have positive cardiac
iomarkers or who have an occluded culprit artery on
ngiography (i.e., STEMI equivalent) (36,42). However,
lthough use of these ECG criteria improves diagnostic
pecificity and may decrease false positive AMI diagnoses,
oncern appropriately exists over a lack of sensitivity (15),
ecause the sensitivity of a Sgarbossa score of 3 or more is
nly approximately 20% (41). Moreover, other studies
uggest that there may be no improvement over clinical
udgment alone (43), and some investigators have even
dvocated for additional ECG criteria to improve sensitiv-
ty. For example, Smith and Dodd (44) found “excessive
iscordance” on ECG, defined as a ratio of ST-segment
levation to S-wave amplitude of 0.20 or less to be 84%
ensitive and 99% specific for left anterior descending
oronary artery occlusion in 148 patients with LBBB and
uspected AMI.
uture Strategies
iven the substantial gap between recent evidence and
urrent recommendations, new diagnostic strategies are
eeded to guide the selection of appropriate patients with
uspected AMI and LBBB for urgent reperfusion therapy.
he clinical need is greater in centers without on-site
rimary PCI, because the implications of false catheteriza-
ion laboratory activation are not as significant as unneces-
ary administration of fibrinolytic therapy. Potential strate-
ies include differential algorithms for transfer to primary
CI centers for patients with LBBB compared with those
ho have ST-segment elevation and normal conduction;
se of more specific ECG criteria; increased use of cardiac
iomarkers, including sensitive assays for cardiac troponins; And bedside echocardiography to improve diagnostic accu-
acy and timely intervention.
Transfer for primary PCI in patients with STEMI at
resentation is equivalent or superior to fibrinolytic therapy
s long as the overall first medical contact-to-balloon time is
ithin 120 minutes (45,46). In general, if the anticipated
ime to reperfusion will exceed this threshold, on-site
brinolytic therapy is recommended. However, because a
ubstantial proportion of patients with LBBB do not have a
TEMI-equivalent AMI, and patients with LBBB have an
verall higher risk of bleeding (more likely female, older,
nd with pre-existing cardiovascular disease, hypertension,
nd congestive heart failure), transfer for primary PCI may be
he preferred strategy, with judicious use of on-site fibrinolysis
eserved for patients highly likely to have a STEMI-equivalent
MI when PCI is not available. This approach seems partic-
larly attractive for most LBBB patients, because the risk-to-
enefit calculation in such patients may favor primary PCI
ven when the delay associated with transfer for primary PCI
xceeds 90 min (47). Additionally, as prehospital triage of chest
ain patients by emergency medical services evolves, patients
ith LBBB may be recognized immediately and routed pref-
rentially to a PCI-capable hospital, as long as delays are within
cceptable time limits.
The use of cardiac biomarkers, specifically the cardiac
roponins I and T, holds additional promise in the diagnosis
f AMI with LBBB. In recent years, the analytic sensitivity
or detection of cardiac troponins has improved 100-fold
48). Newer assays have improved precision as well, which
nables 2 cardiac troponin values with a difference as small
s a few picograms per milliliter to be reliably differentiated.
his is important because although small cardiac troponin
levations can be measured in many chronic cardiac and
oncardiac conditions, and thus lack specificity for AMI, a
ise in absolute levels of troponin strongly supports the
iagnosis of an evolving AMI (49). A rapid rise in troponin
n serial measurement in a patient with LBBB, especially in
he setting of ongoing chest discomfort, could represent a
asked STEMI and may prompt additional diagnostic
esting such as bedside echocardiography (see below), an
nvasive angiographic approach, or administration of fi-
rinolytic therapy if PCI is not available. In contrast, a more
radual rise and lower peak in troponin levels may signal an
STEMI (in which case, transfer to a PCI-capable facility
till would be recommended typically), whereas a static
roponin level would suggest a non-ACS cause. Although
ew data are available, it is becoming increasingly more
easible to accelerate the timing of serial biomarker assess-
ent, such that measurements are performed every 15 min,
ather than every 60 to 90 min, in patients with LBBB and
uspected AMI. Such an approach would minimize reper-
usion delays in those ultimately determined to have
TEMI equivalents. Assessment of rapid biomarker mea-
urements, ideally performed at the point of care, should be
he focus of additional study in patients with suspected
MI and LBBB.
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July 10, 2012:96–105 Management of Patients With LBBB and Suspected AMIFinally, bedside echocardiography may be used as an
adjunctive measure in clinically complex situations to gain
additional insight as to whether a new or presumed new
LBBB is the result of a STEMI-equivalent ACS presenta-
tion. Point-of-care pocket-size echocardiographic devices
can be used by emergency medicine physicians and cardiol-
ogists and have been shown to have high feasibility and
reliability in the assessment of cardiac structure and function
(50). The presence of significant cardiac chamber dilatation,
wall thinning, or chronic valvular dysfunction in the absence
of an acute anterior wall motion abnormality suggests that
the LBBB is more likely secondary to chronic cardiac
disease than AMI. Alternatively, evidence of a hypokinetic
or akinetic segmental wall motion abnormality in the
anterior wall, in the absence of evidence of a prior infarction
(wall thinning, chamber dilatation), may represent a STEMI-
equivalent AMI and should prompt emergent coronary an-
giography. In fact, the use of portable echocardiography to
clarify the diagnosis of STEMI, especially if confounded by
LBBB, has a class IIa indication in the most recent American
College of Cardiology/American Heart Association guidelines
(51). Thus, rapid beside echocardiography represents another
potential strategy for improved clinical decision making in
patients with suspected AMI and LBBB and may be used in
conjunction with the other methods described above.
Investigators have recently proposed changes to the cur-
rent American College of Cardiology/American Heart As-
sociation guidelines for the management of patients with
Figure 3 Proposed Diagnostic Algorithm for Suspected Myocar
ACS  acute coronary syndrome; NSTEMI  non–ST-segment elevation myocardia
STEMI  ST-segment elevation myocardial infarction; UA  unstable angina; othersuspected ACS and LBBB, based on the limited random-
ized trial data demonstrating efficacy of reperfusion therapy
in this subgroup. These include demotion of the Class I,
Level of Evidence: A recommendation that new or pre-
sumed new LBBB be treated as a STEMI equivalent and a
proposal that most patients with LBBB be evaluated for
ST-segment concordance on ECG and positive cardiac
biomarkers to determine the need for urgent reperfusion
therapy (37). We also propose an algorithm for the diag-
nosis and management of these patients (Fig. 3) that
includes a rapid clinical and ECG assessment. Clinically or
hemodynamically unstable patients with possible AMI and
LBBB should be considered for immediate reperfusion
therapy. Among stable patients, ECG assessment should be
performed to determine the presence or absence of ST-
segment concordance criteria in both new and chronic
LBBB. Patients meeting ST-segment concordance criteria
should be treated as having STEMI-equivalent disease and
should receive urgent reperfusion therapy. If concordance
criteria are absent, rapid serial cardiac biomarker testing,
bedside echocardiography, or both should be considered. If
biomarkers increase in the presence of ongoing symptoms or
a large wall motion abnormality in the anterior wall is seen,
emergent angiography should be performed, recognizing
that many of these individuals will still have NSTEMI—
rather than STEMI—equivalents, because our current clin-
ical tools are insufficient to distinguish between the 2
entities when evidence of infarction is present. Given the
nfarction and LBBB
tion; PCI  percutaneous coronary intervention;
viations as in Figures 1 and 2.dial I
l infarc
abbre
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Management of Patients With LBBB and Suspected AMI July 10, 2012:96–105low positive predictive value of LBBB, we recommend that
patients with LBBB and possible ACS be transferred
routinely to a PCI-capable hospital; fibrinolytic therapy
should be considered only if the diagnosis is highly likely
(i.e., meeting Sgarbossa criteria) or the patient is hemody-
namically unstable and transfer to a PCI-capable facility
would result in marked treatment delay. This algorithm
would ensure that urgent reperfusion is delivered to the
highest-risk patients with the greatest likelihood of acute
thrombotic coronary occlusion while taking a more deliberate
approach to diagnosis among individuals in whom the clinical
picture is less clear. Ideally, such a strategy would result in only
small treatment delays in patients with STEMI equivalents
and would be balanced by less exposure to risk for the larger
proportion of patients with non–ST-segment elevation ACS
or non-ACS diagnoses.
Given the significant advancements in efficacy and safety
of AMI treatments and the lack of contemporary evidence
for the existing approach to LBBB, more research encom-
passing additional diagnostic and therapeutic strategies is
needed. Because of the difficulty of diagnosing AMI result-
ing from acute coronary vessel occlusion, inclusion of LBBB
in overall STEMI quality reporting (e.g., door-to-balloon
times and other metrics) also should be reconsidered in light
of the low specificity and positive predictive value of LBBB
for STEMI-equivalent AMI. Removal of LBBB as an
automatic STEMI equivalent would provide more specific
and accurate evaluation of systems of care and quality of
outcomes in STEMI. Therefore, as we evolve toward
improved quality of care and better outcomes for patients,
management of patients with LBBB and suspected AMI
should evolve as well to reflect changing epidemiology, new
observational and clinical trial data, advances in technology,
and continued high-quality evidence-based research.
Conclusions
Patients with a suspected ACS in the setting of LBBB
represent a much more heterogeneous population than
STEMI without BBB and present unique diagnostic and
therapeutic challenges to the clinician. Most patients will
not have an AMI regardless of LBBB chronicity and likely
would not benefit from urgent reperfusion therapy. Current
guideline recommendations and performance measures do
not account for the evolving epidemiology and complexity
of LBBB among patients with possible ACS. We recom-
mend a slightly more judicious approach to diagnosis among
hemodynamically and clinically stable patients with LBBB
who do not have ECG findings highly specific for STEMI.
Moreover, we recommend a higher threshold for pharma-
cological reperfusion than primary PCI, given the lower
probability of an occluded culprit artery and the bleeding
risks of fibrinolytic therapy. The full impact of this ap-
proach, with regard to appropriateness and timeliness of
therapy, as well as outcomes, requires prospective study.Reprints requests and correspondence: Dr. James A. de Lemos,
University of Texas Southwestern Medical Center, 5323 Harry
Hines Boulevard, Dallas, Texas 75390. E-mail: james.delemos@
utsouthwestern.edu.
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